{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:26:26Z","timestamp":1791926786547,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1038\/s41371-020-0336-2","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T18:05:55Z","timestamp":1588010755000},"page":"478-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Primary aldosteronism is a public health issue: challenges and opportunities"],"prefix":"10.1038","volume":"34","author":[{"given":"Renata","family":"Libianto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0948-2072","authenticated-orcid":false,"given":"Peter J.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4620-4976","authenticated-orcid":false,"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"336_CR1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","volume":"390","author":"GBD 2016.","year":"2017","unstructured":"GBD 2016. Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151\u2013210.","journal-title":"Lancet"},{"key":"336_CR2","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","volume":"380","author":"SS Lim","year":"2012","unstructured":"Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224\u201360.","journal-title":"Lancet"},{"key":"336_CR3","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1210\/jc.2016-1472","volume":"101","author":"SC Kayser","year":"2016","unstructured":"Kayser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016;101:2826\u201335.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889\u2013916.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR5","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"336_CR6","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2013-2805","volume":"98","author":"P Mulatero","year":"2013","unstructured":"Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98:4826\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","volume":"60","author":"M Reincke","year":"2012","unstructured":"Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry. Hypertension. 2012;60:618\u201324.","journal-title":"Hypertension"},{"key":"336_CR8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"336_CR9","doi-asserted-by":"crossref","first-page":"597247","DOI":"10.1155\/2015\/597247","volume":"2015","author":"C Catena","year":"2015","unstructured":"Catena C, Colussi G, Sechi LA. Treatment of primary aldosteronism and organ protection. Int J Endocrinol. 2015;2015:597247.","journal-title":"Int J Endocrinol"},{"key":"336_CR10","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/HJH.0000000000001088","volume":"34","author":"P Mulatero","year":"2016","unstructured":"Mulatero P, Monticone S, Burrello J, Veglio F, Williams TA, Funder J. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J Hypertens. 2016;34:2253\u20137.","journal-title":"J Hypertens"},{"key":"336_CR11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.31128\/AJGP-05-18-4587","volume":"47","author":"YY Lim","year":"2018","unstructured":"Lim YY, Shen J, Fuller PJ, Yang J. Current pattern of primary aldosteronism diagnosis: delayed and complicated. Aust J Gen Practice. 2018;47:712\u20138.","journal-title":"Aust J Gen Practice"},{"key":"336_CR12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5694\/mja17.00783","volume":"209","author":"J Yang","year":"2018","unstructured":"Yang J, Fuller PJ, Stowasser M. Is it time to screen all patients with hypertension for primary aldosteronism? Med J Aust. 2018;209:57\u20139.","journal-title":"Med J Aust"},{"key":"336_CR13","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"336_CR14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.4158\/E161332.OR","volume":"22","author":"SJ Galati","year":"2016","unstructured":"Galati SJ, Cheesman KC, Springer-Miller R, Hopkins SM, Krakoff L, Bagiella E, et al. Prevalence of primary aldosteronism in an urban hypertensive population. Endocr Pract. 2016;22:1296\u2013302.","journal-title":"Endocr Pract"},{"key":"336_CR15","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.3399\/bjgp18X694589","volume":"68","author":"SC Kayser","year":"2018","unstructured":"Kayser SC, Deinum J, de Grauw WJ, Schalk BW, Bor HJ, Lenders JW, et al. Prevalence of primary aldosteronism in primary care: a cross-sectional study. Br J Gen Pract. 2018;68:e114\u2013e22.","journal-title":"Br J Gen Pract"},{"key":"336_CR16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1291\/hypres.30.111","volume":"30","author":"R Fogari","year":"2007","unstructured":"Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone\/renin ratio above 25 as a screening test. Hypertens Res. 2007;30:111\u20137.","journal-title":"Hypertens Res"},{"key":"336_CR17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","volume":"42","author":"L Mosso","year":"2003","unstructured":"Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161\u20135.","journal-title":"Hypertension"},{"key":"336_CR18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-0031-1295460","volume":"44","author":"M Stowasser","year":"2012","unstructured":"Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD. Factors affecting the aldosterone\/renin ratio. Horm Metab Res. 2012;44:170\u20136.","journal-title":"Horm Metab Res"},{"key":"336_CR19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1470320312463833","volume":"14","author":"C Volpe","year":"2013","unstructured":"Volpe C, Wahrenberg H, Hamberger B, Thoren M. Screening for primary aldosteronism in a primary care unit. J Renin-Angiotensin-Aldosterone Syst. 2013;14:212\u20139.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"336_CR20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/hr.2010.166","volume":"34","author":"Y Ito","year":"2011","unstructured":"Ito Y, Takeda R, Karashima S, Yamamoto Y, Yoneda T, Takeda Y. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res. 2011;34:98\u2013102.","journal-title":"Hypertens Res"},{"key":"336_CR21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1373\/clinchem.2004.041780","volume":"51","author":"GL Schwartz","year":"2005","unstructured":"Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005;51:386\u201394.","journal-title":"Clin Chem"},{"key":"336_CR22","first-page":"57","volume":"29","author":"C Westerdahl","year":"2011","unstructured":"Westerdahl C, Bergenfelz A, Isaksson A, Nerbrand C, Valdemarsson S. Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area. Scand J Prim Health Care. 2011;29:57\u201362.","journal-title":"Scand J Prim Health Care"},{"key":"336_CR23","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"336_CR24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6:464\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"336_CR25","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/HJH.0000000000001384","volume":"35","author":"E Rossi","year":"2017","unstructured":"Rossi E, Perazzoli F, Negro A, Magnani A. Diagnostic rate of primary aldosteronism in Emilia-Romagna, Northern Italy, during 16 years (2000\u20132015). J Hypertens 2017;35:1691\u20137.","journal-title":"J Hypertens"},{"key":"336_CR26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80\u20135.","journal-title":"Arch Intern Med"},{"key":"336_CR27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5:689\u201399.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"336_CR28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","volume":"50","author":"C Catena","year":"2007","unstructured":"Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50:911\u20138.","journal-title":"Hypertension"},{"key":"336_CR29","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293\u2013300.","journal-title":"J Am Coll Cardiol"},{"key":"336_CR30","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jacc.2017.02.041","volume":"69","author":"G Maiolino","year":"2017","unstructured":"Maiolino G, Calo LA, Rossi GP. The time has come for systematic screening for primary aldosteronism in all hypertensives. J Am Coll Cardiol. 2017;69:1821\u20133.","journal-title":"J Am Coll Cardiol"},{"key":"336_CR31","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.2003-031337","volume":"89","author":"P Mulatero","year":"2004","unstructured":"Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045\u201350.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR32","first-page":"65","volume":"42","author":"G Cooke","year":"2013","unstructured":"Cooke G, Valenti L, Glasziou P, Britt H. Common general practice presentations and publication frequency. Aust Fam physician. 2013;42:65\u20138.","journal-title":"Aust Fam physician"},{"key":"336_CR33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.amjhyper.2004.08.025","volume":"18","author":"M Lamarre-Cliche","year":"2005","unstructured":"Lamarre-Cliche M, de Champlain J, Lacourciere Y, Poirier L, Karas M, Larochelle P. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives. Am J hypertension. 2005;18:56\u201364.","journal-title":"Am J hypertension"},{"key":"336_CR34","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/01.HYP.0000038478.59760.41","volume":"40","author":"P Mulatero","year":"2002","unstructured":"Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, et al. Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism. Hypertension (Dallas, Tex: 1979). 2002;40:897\u2013902.","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"336_CR35","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archinte.1981.00340130033011","volume":"141","author":"K Hiramatsu","year":"1981","unstructured":"Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M. et al.A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981;141:1589\u201393.","journal-title":"Arch Intern Med"},{"key":"336_CR36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1210\/jc.2004-1149","volume":"90","author":"SC Tiu","year":"2005","unstructured":"Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab. 2005;90:72\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/HJH.0b013e3283656b54","volume":"32","author":"PM Jansen","year":"2014","unstructured":"Jansen PM, van den Born BJ, Frenkel WJ, de Bruijne EL, Deinum J, Kerstens MN, et al. Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism. J Hypertens. 2014;32:115\u201326.","journal-title":"J Hypertens"},{"key":"336_CR38","first-page":"8647026","volume":"2018","author":"L Ma","year":"2018","unstructured":"Ma L, Song Y, Mei M, He W, Hu J, Cheng Q, et al. Age-related cutoffs of plasma aldosterone\/renin concentration for primary aldosteronism screening. Int J Endocrinol. 2018;2018:8647026.","journal-title":"Int J Endocrinol"},{"key":"336_CR39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","volume":"66","author":"WF Young","year":"2007","unstructured":"Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007;66:607\u201318.","journal-title":"Clin Endocrinol"},{"key":"336_CR40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/nep.13078","volume":"22","author":"J Yang","year":"2017","unstructured":"Yang J, Shen J, Fuller PJ. Diagnosing endocrine hypertension: a practical approach. Nephrol. 2017;22:663\u201377.","journal-title":"Nephrol"},{"key":"336_CR41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2265.2008.03450.x","volume":"70","author":"WF Young","year":"2009","unstructured":"Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol 2009;70:14\u20137.","journal-title":"Clin Endocrinol"},{"key":"336_CR42","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127\u2013e248.","journal-title":"J Am Coll Cardiol"},{"key":"336_CR43","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J hypertension. 2018;36:1953\u20132041.","journal-title":"J hypertension"},{"key":"336_CR44","unstructured":"RACGP. Guidelines for preventive activities in general practice\u2013Blood pressure [cited June 2019]. https:\/\/www.racgp.org.au\/clinical-resources\/clinical-guidelines\/key-racgp-guidelines\/view-all-racgp-guidelines\/red-book\/prevention-of-vascular-and-metabolic-disease\/blood-pressure."},{"key":"336_CR45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/CIRCOUTCOMES.115.002002","volume":"8","author":"CC Lubitz","year":"2015","unstructured":"Lubitz CC, Economopoulos KP, Sy S, Johanson C, Kunzel HE, Reincke M, et al. Cost-effectiveness of screening for primary aldosteronism and subtype diagnosis in the resistant hypertensive patients. Circulation Cardiovascular Qual Outcomes. 2015;8:621\u201330.","journal-title":"Circulation Cardiovascular Qual Outcomes"},{"key":"336_CR46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1530\/EJE-17-0978","volume":"178","author":"DA Heinrich","year":"2018","unstructured":"Heinrich DA, Adolf C, Rump LC, Quack I, Quinkler M, Hahner S, et al. Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. Eur J Endocrinol. 2018;178:605\u201311.","journal-title":"Eur J Endocrinol"},{"key":"336_CR47","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/cen.12798","volume":"82","author":"GA Kline","year":"2015","unstructured":"Kline GA. Primary aldosteronism: unnecessary complexity in definition and diagnosis as a barrier to wider clinical care. Clin Endocrinol 2015;82:779\u201384.","journal-title":"Clin Endocrinol"},{"key":"336_CR48","doi-asserted-by":"crossref","unstructured":"Maiolino G, Rossitto G, Bisogni V, Cesari M, Seccia TM, Plebani M, et al. Quantitative value of aldosterone-renin ratio for detection of aldosterone-producing adenoma: the aldosterone-renin ratio for primary aldosteronism (AQUARR) study. J Am Heart Assoc. 2017;6.","DOI":"10.1161\/JAHA.117.005574"},{"key":"336_CR49","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/cen.13757","volume":"89","author":"H Hashimura","year":"2018","unstructured":"Hashimura H, Shen J, Fuller PJ, Chee NYN, Doery JCG, Chong W, et al. Saline suppression test parameters may predict bilateral subtypes of primary aldosteronism. Clin Endocrinol. 2018;89:308\u201313.","journal-title":"Clin Endocrinol."},{"key":"336_CR50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/cen.13278","volume":"86","author":"H Kobayashi","year":"2017","unstructured":"Kobayashi H, Haketa A, Ueno T, Ikeda Y, Hatanaka Y, Tanaka S, et al. Scoring system for the diagnosis of bilateral primary aldosteronism in the outpatient setting before adrenal venous sampling. Clin Endocrinol. 2017;86:467\u201372.","journal-title":"Clin Endocrinol."},{"key":"336_CR51","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4158\/EP15982.OR","volume":"22","author":"T Kocjan","year":"2016","unstructured":"Kocjan T, Janez A, Stankovic M, Vidmar G, Jensterle M. A new clinical prediction criterion accurately determines a subset of patients with bilateral primary aldosteronism before adrenal venous sampling. Endocr Pract. 2016;22:587\u201394.","journal-title":"Endocr Pract"},{"key":"336_CR52","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1161\/HYPERTENSIONAHA.114.04453","volume":"65","author":"F Satoh","year":"2015","unstructured":"Satoh F, Morimoto R, Ono Y, Iwakura Y, Omata K, Kudo M, et al. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. Hypertension. 2015;65:1096\u2013102.","journal-title":"Hypertension"},{"key":"336_CR53","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1373\/clinchem.2015.251199","volume":"62","author":"G Eisenhofer","year":"2016","unstructured":"Eisenhofer G, Dekkers T, Peitzsch M, Dietz AS, Bidlingmaier M, Treitl M, et al. Mass spectrometry-based adrenal and peripheral venous steroid profiling for subtyping primary aldosteronism. Clin Chem 2016;62:514\u201324.","journal-title":"Clin Chem"},{"key":"336_CR54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jc.2011-1537","volume":"97","author":"TJ Burton","year":"2012","unstructured":"Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn\u2019s adenomas. J Clin Endocrinol Metab. 2012;97:100\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR55","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/02813430600830931","volume":"24","author":"C Westerdahl","year":"2006","unstructured":"Westerdahl C, Bergenfelz A, Isaksson A, Wihl A, Nerbrand C, Valdemarsson S. High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden. Scand J Prim Health Care. 2006;24:154\u20139.","journal-title":"Scand J Prim Health Care"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41371-020-0336-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-020-0336-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-020-0336-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:25:01Z","timestamp":1684617901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-0336-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["336"],"URL":"https:\/\/doi.org\/10.1038\/s41371-020-0336-2","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"6 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}